Inside the research
LivaNova PLC
LIVN Research profile · latest available data
Price overview
$76.63
▲ +1.19 (+1.6%)
| 52w hi | $85.32 |
|---|---|
| 52w lo | $49.57 |
| Vol | 745.30K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.42
| Short | +0.24 |
|---|---|
| Medium | +0.50 |
| Long | +0.64 |
computed 2026-09-27
Key fundamentals
LivaNova PLC
Healthcare · Medical Devices
| Market cap | $4.21B |
|---|---|
| Enterprise value | $4.06B |
| Trailing P/E | 22.60x |
| Forward P/E | 16.39x |
| EV / EBITDA | 15.60x |
| P / S (ttm) | 2.87x |
| Profit margin | 12.8% |
| Return on equity | 15.4% |
| Revenue growth | +10.8% |
| Earnings growth | +287.8% |
| Debt / equity | 26.56 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.38 | |
| Sector | +0.08 | |
| Technical | +0.09 | |
| Earnings | +0.00 | |
| Sentiment | +0.21 |
macro × 1.00 · 2026-09-27
Business overview
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
Risk Metrics
| Beta vs SPX | 0.96 |
|---|---|
| Corr SPX | 0.39 |
| Annual vol | 40.1% |
| Annual ret | +28.4% |
| Sharpe | 0.71 |
| Max DD | -37.1% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-06-11 | Shareholder Vote, Exhibits | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-02-25 | Earnings Release, Exhibits | read |
| 2026-01-14 | Officer / Director Change | read |
| 2025-11-05 | Earnings Release, Exhibits | read |
| 2025-09-04 | Officer / Director Change, Exhibits | read |
| 2025-08-06 | Earnings Release, Exhibits | read |
| 2025-06-11 | Officer / Director Change, Shareholder Vote… | read |
| 2025-05-21 | Reg FD Disclosure | read |
| 2025-05-07 | Earnings Release, Exhibits | read |
| 2025-03-17 | Reg FD Disclosure | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Tezel Ahmet | Chief Innovation Officer | Sell | 2.67K | $207.94K |
| 2026-08-11 | Tezel Ahmet | Chief Innovation Officer | Withheld for tax | 1.43K | $111.18K |
| 2026-08-11 | Tezel Ahmet | Chief Innovation Officer | Disposal | 8.59K | $668.74K |
| 2026-08-11 | Tezel Ahmet | Chief Innovation Officer | Option exercise | 12.69K | $668.61K |
| 2026-06-15 | WILVER PETER M | Withheld for tax | 486 | $38.73K | |
| 2026-06-15 | SCHERMERHORN TODD C | Option exercise | 4.04K | — | |
| 2026-06-15 | Bianchi Francesco | Withheld for tax | 486 | $38.73K | |
| 2026-06-15 | Bianchi Francesco | Option exercise | 4.04K | — | |
| 2026-06-15 | SCHERMERHORN TODD C | Withheld for tax | 486 | $38.73K | |
| 2026-06-15 | WILVER PETER M | Option exercise | 4.04K | — |
Flow & Concentration
| Insider 180d net | -$304.17K |
|---|---|
| Insider buys / sells | 0 / 2 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 98.5% |
| HHI | 3,477 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| AQR Capital Management | $191.02M | 2.36M |
| State Street Corp | $178.10M | 2.17M |
| Millennium Management | $41.31M | 502.39K |
| Capital Research / Capital World | $24.41M | 296.90K |
| Renaissance Technologies | $9.32M | 113.40K |
| Fidelity / FMR LLC | $5.97M | 4.39M |
| Citadel Advisors | $567.39K | 6.90K |
| T. Rowe Price Group | $5.89K | 71.65K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2016–2025 · 10 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.39B | +1.5% | |
| Gross profit | $203.21M | +15.2% | |
| Operating income | $199.39M | +271.7% | |
| Net income | -$242.47M | — | |
| Cash from ops | $74.91M | +5.5% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $75.44 | $77.46 | $75.12 | $76.63 | 745.30K |
| Sep 24 | $77.26 | $77.45 | $74.11 | $75.44 | 1.06M |
| Sep 23 | $78.39 | $79.02 | $76.70 | $77.16 | 493.10K |
| Sep 22 | $79.19 | $80.19 | $78.18 | $78.49 | 640.50K |
| Sep 21 | $78.39 | $78.63 | $76.83 | $78.17 | 579.20K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →